KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 5, 2017, Stephen Sundlof advised Kindred Biosciences, Inc. (“KindredBio”) of his intention to retire in January of 2018 from his positions as KindredBio’s Executive Vice President of Regulatory Affairs and Quality and Chief Scientific Officer. Dr. Sundlof has agreed to enter into an exclusive consulting agreement with KindredBio to which Dr. Sundlof will render consulting services to KindredBio following the termination of his employment.
Simultaneous with Dr. Sundlof's retirement, Dr. Hangjun Zhan will be promoted to the position of Chief Scientific Officer. Dr. Zhan has over 20 years of experience in the biotechnology sector and is a world-renowned expert in protein design, expression, production, biochemistry, and biophysics. He holds a B.Sc. degree from Zhejiang University, M.S. and Ph.D. degrees from the University of Washington, and completed a post-doctoral fellowship at Harvard Medical School. Dr. Zhan is also the lead author of many peer-reviewed publications and book chapters. Dr. Zhan is currently KindredBio’s Senior Vice President of Biologics Research. Previously, Dr. Zhan held positions at several biotechnology companies including Exelixis, Celera Genomics (Axys), Arris, and Aragen, where he led teams that successfully developed multiple products.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
Kindred Biosciences, Inc. ExhibitEX-99.1 2 pressreleaseseptember2017d.htm PRESS RELEASE Exhibit Exhibit 99.1Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. SundlofSan Francisco,…To view the full exhibit click here
About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.